Ernexa Therapeutics Inc. (NASDAQ:ERNA) Short Interest Up 74.1% in March

Ernexa Therapeutics Inc. (NASDAQ:ERNA) was the target of a large growth in short interest in March. As of March 31st, there was short interest totaling 160,378 shares, a growth of 74.1% from the March 15th total of 92,109 shares. Based on an average daily volume of 1,095,252 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.6% of the company’s stock are sold short.

Ernexa Therapeutics Trading Up 2.6%

Shares of NASDAQ ERNA traded up $0.01 during mid-day trading on Tuesday, reaching $0.20. The company had a trading volume of 136,883 shares, compared to its average volume of 1,529,282. The firm has a 50 day simple moving average of $0.31 and a two-hundred day simple moving average of $0.96. The stock has a market cap of $5.89 million, a P/E ratio of -0.07 and a beta of 6.79. Ernexa Therapeutics has a 52-week low of $0.18 and a 52-week high of $4.02.

Ernexa Therapeutics (NASDAQ:ERNA) last posted its earnings results on Friday, March 13th. The company reported ($0.01) EPS for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Ernexa Therapeutics stock. Susquehanna International Group LLP bought a new stake in Ernexa Therapeutics Inc. (NASDAQ:ERNA) during the third quarter, according to its most recent disclosure with the SEC. The firm bought 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned about 0.39% of Ernexa Therapeutics at the end of the most recent reporting period. 70.55% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Ernexa Therapeutics in a report on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Ernexa Therapeutics currently has an average rating of “Sell”.

Ernexa Therapeutics Company Profile

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.